ResearcherNorthwell HealthNo recent work listed

Hasan Rehman

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 8 November 2026

Known by name at one institution; no external author ID yet. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2020: 1 paper

Papers 1

Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged 65 years or older with advanced pancreatic cancer. Co-author DOI 10.1177/1756284820974912 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Nausheen Hakim · 1 shared paper, 2020 · strength 0.12
- Paper Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged 65 years or older with advanced pancreatic c… DOI 10.1177/1756284820974912 ↗
Shreya Prasad Goyal · 1 shared paper, 2020 · strength 0.12
- Paper Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged 65 years or older with advanced pancreatic c… DOI 10.1177/1756284820974912 ↗
Jeffrey Chi · 1 shared paper, 2020 · strength 0.12
- Paper Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged 65 years or older with advanced pancreatic c… DOI 10.1177/1756284820974912 ↗
Muhammad Wasif Saif · 1 shared paper, 2020 · strength 0.12
- Paper Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged 65 years or older with advanced pancreatic c… DOI 10.1177/1756284820974912 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.